References
- Chlebowski R T, Hendrix S L, Langer R D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003; 289: 3243–3253
- Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
- Collins J A, Blake J M, Crosignani P G. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 2005; 11: 545–560
- Stefanick M L, Anderson G L, Margolis K L, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647–1657
- Opatrny L, Dell'Aniello S, Assouline S, et al. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 2008; 115: 169–175
- Birrell S N, Bentel J M, Hickey T E, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995; 52: 459–467
- Jayo M J, Register T C, Hughes C L, et al. Effects of an oral contraceptive combination with or without androgen on mammary tissues: a study in rats. J Soc Gynecol Invest 2000; 7: 257–265
- Dimitrakakis C, Zhou J, Wang J, et al. A physiological role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003; 10: 292–298
- Hofling M, Lindén Hirschberg A, Skoog L, et al. Testosterone addition inhibits estrogen-progestogen induced breast cell proliferation in postmenopausal women. Menopause 2007; 14: 183–190
- Conner P, Christow A, Kersemaekers W, et al. A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen–progestogen treatment. Climacteric 2004; 7: 50–58
- Beato M, Klug J. Steroid hormone receptors: an update. Hum Reprod Update 2000; 6: 225–236
- Kollara A, Kahn H J, Marks A, et al. Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. Breast Cancer Res Treat 2001; 67: 245–253
- Shan L, Yang Q, Nakamura M, et al. Active allele loss of the androgen receptor gene contributes to loss of androgen receptor expression in female breast cancers. Biochem Biophys Res Commun 2000; 275: 488–492
- Isola J J. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993; 170: 31–35
- Reid S E, Murthy M S, Kaufman M, et al. Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 1996; 83: 1037–1046
- Delehedde M, Lyon M, Sergeant N, et al. Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland. J Mammary Gland Biol Neoplasia 2001; 6: 253–273
- Alowami S, Troup S, Al-Haddad S, et al. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 2003; 5: R129–R135
- Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003; 98: 474–483
- Beauvais D M, Rapraeger A C. Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2004; 2: 3
- Roskelley C D, Bissell M J. Dynamic reciprocity revisited: a continuous, bidirectional flow of information between cells and the extracellular matrix regulates mammary epithelial cell function. Biochem Cell Biol 1995; 73: 391–397
- Stanley M J, Stanley M W, Sanderson R D, et al. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 1999; 112: 377–383
- Maeda T, Alexander C M, Friedl A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res 2004; 64: 612–621
- Leivonen M, Lundin J, Nordling S, et al. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004; 67: 11–18
- Cline J M, Söderqvist G, Register T C, et al. Assessment of hormonally active agents in the reproductive tract of female nonhuman primates. Toxicol Pathol 2001; 29: 84–90
- Cline J M, Register T C, Clarkson T B. Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause 2002; 9: 422–429
- Adams M R, Register T C, Golden D L, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 217–221
- Santen R J. Risk of breast cancer with progestins: critical assessment of current data. Steroids 2003; 68: 953–964
- Birkhäuser M H, Barlow D H, Notelovitz M, Rees M C. Health Plan for the Adult Woman. Taylor and Francis, London 2005
- Lillie E O, Bernstein L, Ingles S A, et al. Polymorphism in the androgen receptor and mammographic density in women taking and not taking estrogen and progestin therapy. Cancer Res 2004; 64: 1237–1241
- Lobaccaro J M, Lumbroso S, Belon C, et al. Male breast cancer and the androgen receptor gene. Nat Genet 1993; 5: 109–111
- Haiman C A, Brown M, Hankinson S E, et al. The androgen receptor CAG repeat polymorphism and risk breast cancer in the Nurses' Health Study. Cancer Res 2002; 62: 1045–1049
- Lundström E, Sahlin L, Skoog L, et al. Expression of Syndecan-1 in histologically normal breast tissue from postmenopausal women according to mammographic density. Climacteric 2006; 9: 277–282
- Harvey J A, Santen R J, Petroni G R, et al. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor and proliferation indices. Menopause 2008; 15: 67–73
- Löfgren L, Sahlin L, Jiang S, et al. Expression of syndecan-1 in paired samples of normal and malignant breast tissue from postmenopausal women. Anticancer Res 2007; 27: 3045–3050
- Shekhar M P, Pauley R, Heppner G. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res 2003; 5: 130–135
- Conner P. Breast response to menopausal hormone therapy: aspects on proliferation, apoptosis and mammographic density. Ann Med 2007; 39: 28–41
- Stefanick M L, Anderson G L, Margolis K L, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647–1657
- Chen W Y, Manson J E, Hankinson S E, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006; 166: 1027–1032